Sarcoma Risk After Laparoscopic Surgery: A Retrospective Analysis

e21529 Background: The US Food and Drug Administration (FDA) advisory panel has discouraged the use of laparoscopic power morcellators (LPM) for removal of uterus or uterine fibroids in April 2014. The minimal invasive approach for surgery of uterine fibroids is considered standard of care. Does the sarcoma risk abundant the laparoscopic approach with morcellment? The retrospective Analysis evaluates the incidence rates and the prognosis of occult uterine leiomyosarcoma (LMS) Methods: The medical reports of 594 Patients with benigne surgery for uterine fibroids between 2008 and 2013 were anaylsed for occult LMS to confirm the incidence rate. The clinical cancer registry Regensburg (Germany) registered 71 known patients between 2004 and 2013 with uterine LMS. Outcome, survival and recurrence rates were evaluated for Patients who underwent laparoscopic and abdominal surgery. The significance of preopereative uterine LMS diagnostical tools such as magnetic resonance imaging (MRI), elevated lactate dehydrogenase level, rapid growth, and pre/post menopausal bleeding were evaluated in the cohort. Results: In our Cohort of 594 patients 0,51% were diagnosed with an occult LMS with laparoscopic surgery and 0,34% with open surgery. The prognosis of the patients with laparocscopic surgery was not significantly different to those of an abdominal surgery. Conclusions: The minimal invasive approach is according to our data still standard of care in the treatment of uterine fibroids.